Associations between ACA-related policies and a clinical recommendation with HPV vaccine initiation
- PMID: 33866458
- DOI: 10.1007/s10552-021-01430-4
Associations between ACA-related policies and a clinical recommendation with HPV vaccine initiation
Abstract
Purpose: We examined associations between the 2010 Affordable Care Act (ACA) provisions, 2011 Advisory Committee on Immunization Practices (ACIP) recommendation, and 2014 ACA-related health insurance reforms with HPV vaccine initiation rates by sex and health insurance type.
Methods: Using 2009-2015 public and private health insurance claims for 551,764 males and females aged 9-26 years (referred to as youth) from Maine, New Hampshire, and Massachusetts, we conducted linear regression models to examine the associations between three policy changes and HPV vaccine initiation rates by sex and health insurance type.
Results: In 2009, HPV vaccine initiation rates for males and females were 0.003 and 0.604 per 100 enrollees, respectively. Among males, the 2010 ACA provisions and ACIP recommendation were associated with significant increases in HPV vaccine uptake among those with private plans (0.207 [0.137, 0.278] and 0.419 [0.353, 0.486], respectively) and Medicaid (0.157 [0.083, 0.230] and 0.322 [0.257, 0.386], respectively). Among females, the 2010 ACA provisions were associated with significant increases in HPV vaccine uptake among Medicaid enrollees only (0.123 [0.033, 0.214]). The ACA-related health insurance reforms were associated with significant increases in HPV vaccine uptake for male and female Medicaid enrollees (0.257 [0.137, 0.377] and 0.214 [0.102, 0.327], respectively), but no differences among privately insured youth. By 2015, there were no differences in HPV vaccine initiation rates between males (0.278) and females (0.305).
Conclusions: Both ACA provisions and the ACIP recommendation were associated with significant increases in HPV vaccine initiation rates among privately and publicly insured males in three New England states, closing the gender gap. In contrast, females and youth with private insurance did not exhibit the same changes in HPV vaccine uptake over the study period.
Keywords: Affordable care act; Health disparity; Human papillomavirus; Policy; Vaccine.
Similar articles
-
Associations between insurance-related affordable care act policy changes with HPV vaccine completion.BMC Public Health. 2021 Feb 6;21(1):304. doi: 10.1186/s12889-021-10328-4. BMC Public Health. 2021. PMID: 33549075 Free PMC article.
-
ACA and Medicaid Expansion Increased Breast Pump Claims and Breastfeeding for Women with Public and Private Insurance.Womens Health Issues. 2022 Mar-Apr;32(2):114-121. doi: 10.1016/j.whi.2021.10.005. Epub 2021 Nov 19. Womens Health Issues. 2022. PMID: 34802860
-
The Affordable Care Act and change in human papillomavirus (HPV) vaccine uptake in the United States.Vaccine. 2025 Mar 19;50:126842. doi: 10.1016/j.vaccine.2025.126842. Epub 2025 Feb 5. Vaccine. 2025. PMID: 39914253
-
Human Papillomavirus Infection and Vaccination.J Pediatr Nurs. 2016 Mar-Apr;31(2):e155-66. doi: 10.1016/j.pedn.2015.10.005. Epub 2015 Nov 14. J Pediatr Nurs. 2016. PMID: 26586310 Review.
-
A Critical Analysis of Obamacare: Affordable Care or Insurance for Many and Coverage for Few?Pain Physician. 2017 Mar;20(3):111-138. Pain Physician. 2017. PMID: 28339427 Review.
Cited by
-
Affordable Care Act state Medicaid expansion and human papillomavirus vaccination among adolescent and young adult US women: A national study.Health Serv Res. 2023 Aug;58(4):792-799. doi: 10.1111/1475-6773.14133. Epub 2023 Jan 30. Health Serv Res. 2023. PMID: 36632778 Free PMC article.
-
Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics' impact.Saudi Pharm J. 2022 Dec;30(12):1725-1735. doi: 10.1016/j.jsps.2022.10.001. Epub 2022 Oct 7. Saudi Pharm J. 2022. PMID: 36601511 Free PMC article.
References
-
- Markowitz LE, Dunne EF, Saraiya M et al (2014) Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 63(RR-05):1–30 - PubMed
-
- Markowitz LE, Dunne EF, Saraiya M et al (2007) Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 56(RR-2):1–24 - PubMed
-
- Centers for Disease Control and Prevention (2010) FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 59(20):630–632
-
- Centers for Disease Control and Prevention (2011) Recommendations on the use of quadrivalent human papillomavirus vaccine in males–advisory committee on immunization practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60(50):1705–1708
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous